PFS. (A) PFS of patients randomized to ibrutinib-rituximab (IR) arm of E1912 trial. (B) PFS of IR arm of E1912 trial by IGHV mutation status. (C) PFS of patients while on treatment; all patients on the IR arm of E1912 trial. Patients discontinuing ibrutinib for reason other than progression or death are censored at the time of off treatment. (D) PFS while on treatment for IR arm of E1912 trial by IGHV mutation status. Patients discontinuing ibrutinib for reason other than progression or death are censored at the time of off treatment.